FDARxBench: Benchmarking regulatory and clinical reasoning on FDA generic drug assessment

Betty Xiong, Jillian Fisher, Benjamin Newman, Meng Hu, Shivangi Gupta, Yejin Choi, Lanyan Fang, Russ B Altman


Abstract
We introduce an expert-guided, real-world benchmark for evaluating document-grounded question-answering (QA) motivated by generic drug assessment, using the U.S. Food and Drug Administration (FDA) drug label documents. Drug labels contain rich but heterogeneous clinical and regulatory information, making accurate question answering difficult for current language models. In collaboration with FDA regulatory assessors, we introduce FDARxBench, and construct a multi-stage pipeline for generating high-quality, expert-guided, LLM-assisted, QA examples spanning factual, multi-hop, and refusal tasks, and design evaluation protocols to assess both open-book and closed-book reasoning. Experiments across proprietary and open-weight models reveal substantial gaps in factual grounding, long-context retrieval, and safe refusal behavior. While motivated by FDA generic drug assessment needs, this benchmark also provides a substantial foundation for challenging regulatory-grade evaluation of label comprehension.
Anthology ID:
2026.emnlp-main.191
Volume:
Proceedings of the 2026 Conference on Empirical Methods in Natural Language Processing
Month:
October
Year:
2026
Address:
Budapest, Hungary
Editors:
Hung-Yi Lee, Sunipa Dev, Jessy Li, Desmond Elliott
Venue:
EMNLP
SIG:
SIGDAT
Publisher:
Association for Computational Linguistics
Note:
Pages:
4377–4401
Language:
URL:
https://aclanthology.org/2026.emnlp-main.191/
DOI:
Bibkey:
Cite (ACL):
Betty Xiong, Jillian Fisher, Benjamin Newman, Meng Hu, Shivangi Gupta, Yejin Choi, Lanyan Fang, and Russ B Altman. 2026. FDARxBench: Benchmarking regulatory and clinical reasoning on FDA generic drug assessment. In Proceedings of the 2026 Conference on Empirical Methods in Natural Language Processing, pages 4377–4401, Budapest, Hungary. Association for Computational Linguistics.
Cite (Informal):
FDARxBench: Benchmarking regulatory and clinical reasoning on FDA generic drug assessment (Xiong et al., EMNLP 2026)
Copy Citation:
PDF:
https://aclanthology.org/2026.emnlp-main.191.pdf